{"id":"W3152878368","doi":"10.1016/j.annonc.2021.04.008","title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Foundation Medicine; Samsung; Genentech; EMD Serono; Otsuka Pharmaceutical; Chugai Pharmaceutical; Seagen; Incyte; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Carboplatin; Internal medicine; Oncology; Lung cancer; Hazard ratio; Placebo; Chemotherapy; Progression-free survival; Cisplatin; Confidence interval; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002691567,0.0003374005,0.001523204,0.0004547394,0.00005466673,0.0000196044,0.0001515357,0.000155279,0.00142662],"category_scores_gemma":[0.0001049367,0.0002171266,0.0001987771,0.002016737,0.0002266431,0.0001034932,0.00004277465,0.0002653532,0.000006704377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002268799,"about_ca_system_score_gemma":0.001682465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002273651,"about_ca_topic_score_gemma":0.01099818,"domain_scores_codex":[0.9973603,0.0003102701,0.0007839003,0.0005741146,0.0004946546,0.0004767095],"domain_scores_gemma":[0.9978784,0.0002635453,0.0005316703,0.000554777,0.0006252994,0.000146319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.533803,0.004076429,0.3939049,0.0002514015,0.008175367,0.001142661,0.002183574,0.0001949368,0.000514758,0.000008456129,0.001011283,0.05473321],"study_design_scores_gemma":[0.1227782,0.03141147,0.8259475,0.0006090401,0.002837969,0.00006888933,0.0009629441,0.0005635494,0.005757387,0.00002238152,0.008437739,0.0006029581],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822804,0.0001171542,0.0001720838,0.0006730835,0.00002865362,0.01505776,0.00008727033,0.00003597393,0.001547651],"genre_scores_gemma":[0.9895866,0.00003065927,0.002986712,0.0008755791,0.00003527625,0.005251497,0.0003723366,0.00004298456,0.000818343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4320426,"threshold_uncertainty_score":0.9994862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07969916344976641,"score_gpt":0.3712988432856288,"score_spread":0.2915996798358624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}